Financial Performance & Construction - Sky Harbour's construction is accelerating, leading to increasing revenues[20] - Sky Harbour Capital is experiencing a step up in 2025 with three new campus openings[32] - A drawdown "warehouse" bank facility is expected to provide $200 million for construction[59] - The warehouse facility is projected to fund construction of ADS2, BDL, POU1, SLC, and TTN[61] Leasing & Revenue - Stabilized campuses are enjoying higher-than-forecast revenue[70] - Potential revenue opportunity at SHER stabilization shows a 23% premium with an average expected revenue of $35.75 per rentable square foot compared to the 2022 CBRE projected $29.08, and a 38% premium with the highest expected revenue of $40.06 per rentable square foot[44] - Q2 Revenue Run Rate for SGR is $1.4 million, $5.0 million for BNA, $6.3 million for OPF, $4.0 million for SJC, and $2.9 million for DVT[48] Site Acquisition & Development - Sky Harbour reaffirms guidance of 5 new ground lease announcements by year-end[42] - The company has secured 18 airport ground leases and is targeting Tier-1 SHER locations[70] - Construction has commenced in OPF2, with completion expected by Q2 2026[70] Operational Strategy - Sky Harbour is transitioning to a centralized operating model[70] - The company is focused on maximizing revenue capture and is on course to meet its 2025 acquisitions target[74]

Q2 2025 Earnings Supplemental August 12th, 2025 Cautionary Statement Regarding Forward-Looking Statements This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts. These forward-looking statements relate to matters such as our industry, business st ...

Financial Performance - Adjusted Distributable Earnings (DE) reached R$7576 million, a 30% increase year-over-year [14, 98] - Adjusted DE per share was R$120, up 9% year-over-year [10, 14, 97] - Fee Related Revenues totaled R$2327 million, an 85% increase year-over-year [14, 28, 31] - Fee Related Earnings (FRE) were R$652 million, a 5% increase year-over-year [14, 36] Assets Under Management (AUM) - Total AUM reached R$3041 billion, up 339% year-over-year [19] - New capital formation in 2Q'25 totaled R$36 billion [19] - Portfolio appreciation of R$81 billion occurred during the quarter [19] Segment Performance - Global IP&S AUM ended the quarter at R$230 billion [61, 62] - Credit AUM totaled R$30 billion, up 258% year-over-year [65, 67] - Private Equity AUM reached R$16 billion, up 2% year-over-year [71, 73] - Real Assets AUM totaled R$12 billion, up 14% year-over-year [80, 82]

CoreWeave Q2'25 Earnings Presentation August 12, 2025 1 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of applicable securities laws. Such statements are based on our current expectations, forecasts and assumptions and involve risks and uncertainties. These statements include, but are not limited to, statements related to our business; our strategy; our market opportunity and future growth; market trends; impact of investments in sales and marketing; an ...

Q4 FY25 Performance - Revenue reached $480.7 million[9,10,11,13], a 16% increase QoQ[8] and a 67% increase YoY[8] - Non-GAAP gross margin was 37.8%[10], compared to 35.2% in Q3 FY25[10] and 27.8% in Q4 FY24[10] - Non-GAAP operating income was $72.3 million[10], resulting in a 15.0% operating margin[10] - Non-GAAP diluted EPS was $0.88[10], compared to $0.57 in Q3 FY25[10] and $(0.13) in Q4 FY24[10] Segment Performance - Cloud & Networking revenue was $424.1 million[11] - Industrial Tech revenue was $56.6 million[11] Key Growth Drivers - Strong cloud demand, particularly from hyperscale customers, drove revenue growth[8] - Cloud module shipments exceeded the 50% QoQ growth target[8] - EML business approximately doubled compared to Q4 FY24[8] Q1 FY26 Guidance (Non-GAAP) - Revenue is projected to be between $510 million and $540 million[13] - Operating margin is expected to be between 16.0% and 17.5%[13] - Diluted EPS is projected to be between $0.95 and $1.10[13]

Financial Performance - Total revenue increased by 81% year-over-year, reaching $181.4 million in Q2 2025, compared to $100 million in Q2 2024[11] - Molecular Profiling Services revenue grew by 86% year-over-year, amounting to $162.9 million in Q2 2025, up from $87.7 million in Q2 2024[11] - Pharma R&D Services revenue increased by 49% year-over-year, reaching $18.5 million in Q2 2025, compared to $12.4 million in Q2 2024[11] - Clinical ASP improved by 52%, rising from $2,138 in Q2 2024 to $3,256 in Q2 2025[15] - Gross margin increased by 2,514 basis points year-over-year, reaching 62.7% in Q2 2025[15, 42] - Adjusted EBITDA turned positive, reaching $16.7 million in Q2 2025, compared to a loss of $50.9 million in Q2 2024[15, 34] - Free Cash Flow turned positive, reaching $5.9 million in Q2 2025, compared to a loss of $65.5 million in Q2 2024[15, 34] Operational Highlights - Clinical volume grew by 22%, with 50,032 clinical cases completed in Q2 2025[15] - The company's molecular dataset surpassed 900,000+ comprehensive tumor patient profiles, including over 529,000 Whole Exomes and 580,000 Whole Transcriptomes[15, 21] - Caris Assure ASP increased 58.7% year-over-year to $2,519 in Q2 2025[40] - MI Profile ASP increased 53.1% year-over-year to $3,379 in Q2 2025[40] Strategic Initiatives - The Partner Oncology Alliance (POA) expanded to 97 sites with over 1,100 publications[15, 23] - A landmark Caris Assure study was published, validating the single assay across the cancer care continuum[15, 26]

NASDAQ: SCWO Investor Presentation August 12, 2025 ©2025 374Water Inc. All Rights Reserved. This document and the information set forth herein are the property of 374Water. Clean & Sustainable Destruction of Organic Waste Second Quarter 2025 Strategic and Commercial Update and Financial Results Conference Call Cautionary Statement Regarding Forward-Looking Statements This presentation and various remarks we make during this presentation contain "forward-looking statements" of 374Water Inc. ("374Water," "the ...

Clinical Trial Updates - Data from the ASPEN-06 trial highlights CD47 expression as a key predictive biomarker, demonstrating a compelling clinical response of evorpacept activity in HER2+ gastric cancer[12] - The Phase 2 ASPEN-Breast evorpacept trial design was updated to enable a CD47 and HER2 biomarker-driven strategy in a single-arm study[12] - Dose escalation was completed in the Sanofi-sponsored trial of evorpacept with SARCLISA® and dexamethasone in previously treated multiple myeloma, with Sanofi moving into dose optimization[12] - The first patient is anticipated to be enrolled in August in the phase 1 clinical trial of the novel EGFR-targeted antibody-drug conjugate (ADC), ALX2004[12] Financial Strategy - Focus on evorpacept in ASPEN-Breast and ALX2004, while pausing ASPEN-CRC, results in cash runway extended into Q1 2027[12] - The company had cash, cash equivalents, and investments of $84 million as of June 30, 2025[100] Upcoming Milestones - ASPEN-06 CD47 expression data update is expected in Q4 2025[12] - Initial safety data for ALX2004 is anticipated in 1H 2026[12] - ASPEN-breast interim data readout is expected in Q3 2026[12] ASPEN-06 Trial Results - In the ITT population, Evorpacept + TRP showed a 41% ORR compared to 27% in the TRP control arm[42] - In patients with HER2-positivity confirmed by fresh biopsy or ctDNA, evorpacept demonstrated a 49% ORR compared to 245% in control[45] - In patients with HER2+ and CD47-high gastric cancer (n=43), evorpacept + TRP had a 65% ORR versus 26% ORR for TRP[53] ASPEN-Breast Trial - In breast cancer patients with confirmed HER2-positivity, evorpacept + zanidatamab had a 56% confirmed ORR[63]

Zorevunersen for Dravet Syndrome - Stoke Therapeutics is developing zorevunersen as a potential disease-modifying medicine for Dravet syndrome [16] - Initial 70mg doses of zorevunersen demonstrated substantial and sustained reductions in convulsive seizure frequency [18] - Ongoing zorevunersen treatment showed substantial and durable reductions in major motor seizure frequency in OLE studies [21] - 36-month OLE data shows continuing improvements in cognition and behavior with zorevunersen treatment [56] - The EMPEROR Phase 3 study is designed to assess disease modification in Dravet syndrome with a dosing regimen of 2x70mg followed by 2x45mg over a 52-week treatment period [31, 32] - The EMPEROR Phase 3 study has dosed its first patient in August 2025 and anticipates data in 2H 2027, randomizing approximately 170 patients across ~70 global sites [35] STK-002 for Autosomal Dominant Optic Atrophy (ADOA) - Approximately 65-90% of ADOA cases are caused by mutations in one allele of the OPA1 gene, leading to haploinsufficiency [64] - Up to 46% of ADOA patients are registered as legally blind [65] - Preclinical findings support further development of STK-002, showing increased OPA1 protein and ATP-linked respiration [70] - A Phase 1 study of STK-002 in ADOA patients is underway in the UK, involving 21 patients aged ≥18 to <55 years receiving single ascending doses (0.1, 0.3, 0.5, & 0.7 mg/eye) [76]

Company Overview and Strategy - Mobile Infrastructure owns a diversified portfolio of parking assets primarily in the Midwest and Southwest and aims to improve revenue consistency and NOI margin through conversion from leased to managed contracts[6] - The company's strategic plan focuses on driving NOI growth through asset profile optimization, pivoting to management contracts, implementing an asset management approach, and exploring ancillary revenue opportunities like EV charging[14] - As of June 30, 2025, 29 out of 40 assets have been converted to management contracts, with plans to convert the remaining assets in 2026-2027, which is expected to accelerate revenue growth and cost savings[25] Financial Performance and Valuation - The company's Net Asset Value (NAV) is $7.25 per share, indicating a potentially attractive valuation compared to the higher replacement cost of its assets[6] - For the quarter ended June 30, 2025, managed property revenue was $7441 thousand, while base rental income was $1447 thousand, and percentage rental income was $104 thousand[49] - Net Operating Income (NOI) for the quarter ended June 30, 2025, was $5435 thousand, a decrease of 35% compared to $5633 thousand for the same period in 2024[49] - Adjusted EBITDA for the quarter ended June 30, 2025, was $3846 thousand, compared to $4074 thousand for the same period in 2024[50] Market and Acquisition Strategy - The U S parking industry generates approximately $131 billion in annual revenue, representing about 1% of the U S GDP[28] - The company has a $300 million pipeline of potential acquisitions and intends to become the acquirer of choice in the parking industry through its unique, tax-efficient acquisition program[6, 45]